The Post-hospitalisation COVID-19 study (PHOSP-COVID) is collaborating with the
National COVID-19 Chest Imaging Database (NCCID). PHOSP-COVID is a national
consortium, led by experts at the University Hospitals of Leicester NHS Trust
under the umbrella of the NIHR Leicester Biomedical Research Centre. It aims
to understand and improve long-term health outcomes for patients who have been
discharged from hospital with confirmed or suspected COVID-19.
PHOSP-COVID has been set up and funded as a long term research study to recruit
10,000 patients who have been hospitalised with COVID-19. Over the course of a
year, clinical assessments will track patients to gain a comprehensive picture
of the impact COVID-19 has had on longer term health outcomes across the UK.
PHOSP-COVID will be collecting samples and scans for patients from a network of
Trusts in the UK (see here for the full list).
PHOSP-COVID is collaborating with the NCCID initiative to ensure that the same
sites included in the PHOSP-COVID network are also contributing towards the
NCCID database. This is so that PHOSP-COVID researchers are able to access
important data already collected for patients via the NCCID study in order
to accompany the longitudinal data PHOSP-COVID are collecting for patients.
Important information for data collection sites
If you are contacted by the PHOSP-COVID study to upload data but are
not yet contributing to the NCCID, we would ask that you follow the
instructions here to ensure you are contributing
to both studies.
The International Severe Acute Respiratory and emerging Infection Consortium (ISARIC) was founded in 2011 to prevent illness and deaths from infectious disease outbreaks. It is a global federation of clinical research networks, providing a proficient, coordinated and agile research response to outbreak-prone infectious disease.
This consortium is responding to the current COVID-19 outbreak by creating tools for investigators to collect and store data in a standardised way and has supported clinical trials of treatments. One of these tools, the ‘Clinical Characterisation Protocol‘ (CCP), has been co-developed by HDR UK members, in consultation with colleagues at the World Health Organisation.
The CCP sets out how data and biological samples from patients with COVID-19 should be collected, regardless of where in the world they are. It’s the product of many years of discussion among international investigators from a wide range of scientific and medical disciplines. Work to develop this protocol started in response to Middle Eastern Respiratory Syndrome coronavirus (MERS-CoV) in 2012-2013, Influenza H7N9 in 2013, viral haemorrhagic fever (Ebolavirus) in 2014, Monkeypox & MERS-CoV in 2018 and Tick-borne encephalitis virus (TBEV) in 2019. It is now being used for COVID-19 .
ISARIC-4C will augment the aforementioned datasets, which have played a central role in the UK’s research response to COVID-19, with imaging data from the NCCID. This will support improvements in the understanding, diagnosis and prognosis of the disease through the availability of data that comprises a wide range of variables such as clinical measurements, ‘omics’ assays, and radiology scans. For example, the linkage facilitated by this Agreement may lead to the development of a COVID-19 risk score that extends the one developed by the ISARIC consortium through the use of chest-imaging data.